Compare SRAD & VKTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SRAD | VKTX |
|---|---|---|
| Founded | 2001 | 2012 |
| Country | Switzerland | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Programming Data Processing | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.8B | 3.7B |
| IPO Year | 2021 | 2014 |
| Metric | SRAD | VKTX |
|---|---|---|
| Price | $11.35 | $24.95 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 23 | 21 |
| Target Price | $17.38 | ★ $95.32 |
| AVG Volume (30 Days) | 2.3M | ★ 3.8M |
| Earning Date | 11-03-2026 | 10-28-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $17.94 | N/A |
| Revenue Next Year | $5.04 | N/A |
| P/E Ratio | $49.48 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $11.39 | $23.82 |
| 52 Week High | $24.17 | $43.10 |
| Indicator | SRAD | VKTX |
|---|---|---|
| Relative Strength Index (RSI) | 37.21 | 40.45 |
| Support Level | N/A | $23.82 |
| Resistance Level | $13.62 | $36.01 |
| Average True Range (ATR) | 0.61 | 1.82 |
| MACD | -0.22 | -0.10 |
| Stochastic Oscillator | 0.13 | 0.56 |
Sportradar Group AG is a technology platform enabling next-generation engagement in sports, and a provider of B2B solutions to the sports betting industry. It generates revenue through two primary sources: subscription-based revenue and revenue sharing. Geographically, it operates in North America, Africa, AsiaPac & Middle East, Europe, and LATAM & Caribbean.
Viking Therapeutics Inc is a healthcare service provider. The company specializes in the area of biopharmaceutical development focused on metabolic and endocrine disorders. The company's clinical program pipeline consists of VK2809, VK5211, and VK0214 products. VK2809 and VK0214 are orally available, tissue and receptor-subtype-selective agonists of the thyroid hormone receptor beta. VK5211 is an orally available, non-steroidal selective androgen receptor modulator.